|
MechanismHMG-CoA reductase inhibitors [+2] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Switzerland |
First Approval Date25 Jun 1990 |
100 Clinical Results associated with Sigillata Ltd.
0 Patents (Medical) associated with Sigillata Ltd.
100 Deals associated with Sigillata Ltd.
100 Translational Medicine associated with Sigillata Ltd.